Acrivon Therapeutics, Inc. Stock Price, News & Analysis

Welcome to our dedicated page for Acrivon Therapeutics news (Ticker: ACRV), a resource for investors and traders seeking the latest updates and insights on Acrivon Therapeutics stock.

Acrivon Therapeutics, Inc. (Nasdaq: ACRV) is a clinical stage biopharmaceutical company that regularly issues news about its precision oncology pipeline and Generative Phosphoproteomics AP3 platform. Company announcements describe progress for its lead CHK1/CHK2 inhibitor ACR-368 in a registrational-intent Phase 2 or Phase 2b trial in endometrial cancer, as well as updates on ACR-2316, a WEE1/PKMYT1 inhibitor in Phase 1 development, and AP3-enabled preclinical programs such as the CDK11-targeting candidate ACR-6840.

News releases from Acrivon often cover interim clinical data, including response rates and tumor shrinkage in AP3-prioritized solid tumor types, details on dose-escalation cohorts, and observations of drug target engagement based on AP3 profiling. The company also reports on regulatory designations, such as FDA Fast Track status for ACR-368 monotherapy in endometrial cancer and FDA Breakthrough Device designation for the ACR-368 OncoSignature assay, as well as trial design elements like biomarker-selected and biomarker-unselected arms and combinations with ultra-low dose gemcitabine.

Investors and observers following ACRV news can expect updates on Acrivon’s presentations at scientific conferences, including AACR and AACR-NCI-EORTC, where the company highlights AP3-based mechanistic data, the AP3 KaiSR generative AI model, and pharmacodynamic insights for ACR-2316 and other candidates. The company also issues periodic financial results and business highlights, summarizing cash resources, research and development activities, and anticipated clinical and regulatory milestones for its AP3-enabled pipeline.

This ACRV news page aggregates these press releases and related coverage, providing a centralized view of Acrivon’s reported clinical progress, platform developments, and corporate updates over time.